Clinical Trials Browser

OTHER × darolutamide × Head & Neck × Clear all

NCT06145308 2025-09-15

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

Phase 2 Recruiting

Salivary Gland Neoplasms

NCT05694819 2025-05-22

Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)

Phase 2 Active not recruiting

Salivary Gland Neoplasms, Bulbo-Spinal Atrophy, X-Linked